story of the week
Activity and Safety of the Novel Oral Selective Androgen Receptor Modulator Enobosarm in Patients With AR+, ER+, and HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
Lancet Oncol 2024 Feb 08;[EPub Ahead of Print], C Palmieri, H Linden, SN Birrell, S Wheelwright, E Lim, LS Schwartzberg, AR Dwyer, TE Hickey, HS Rugo, P Cobb, JA O'Shaughnessy, S Johnston, A Brufsky, WD Tilley, B OvermoyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.